Award
National Heart, Lung, and Blood Institute 3R41HL180136-01S1
Repurposing Pyrvinium as an Inhalation Therapy for Idiopathic Pulmonary Fibrosis
Recipient
Not Specified
Award Amount
$6,500.00
Ceiling
$6,500.00
Awarded
July 22, 2026
Identifier
3R41HL180136-01S1
Research grant awarded by NHLBI to develop inhalation therapy for idiopathic pulmonary fibrosis using repurposed Pyrvinium drug, involving animal and human tissue studies.
Description
This is a research grant opportunity for developing inhalation therapy for IPF using repurposed drug Pyrvinium. The project involves animal models and ex vivo human tissue studies. The award amount is USD 6,500, with a project duration from September 20, 2025, to August 31, 2027. The funding agency is the NHLBI, part of NIH.